These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28494193)

  • 1. Long-term trends in invasive pneumococcal disease in Manitoba, Canada.
    Mahmud SM; Sinnock H; Mostaço-Guidolin LC; Pabla G; Wierzbowski AK; Bozat-Emre S
    Hum Vaccin Immunother; 2017 Aug; 13(8):1884-1891. PubMed ID: 28494193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Euro Surveill; 2017 Mar; 22(10):. PubMed ID: 28300529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
    Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
    Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S; Hillier K; Lim GH; Harris TM; Wilson SE; Deeks SL
    PLoS One; 2019; 14(12):e0226353. PubMed ID: 31834926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure.
    Camilli R; D'Ambrosio F; Del Grosso M; Pimentel de Araujo F; Caporali MG; Del Manso M; Gherardi G; D'Ancona F; Pantosti A;
    Vaccine; 2017 Aug; 35(35 Pt B):4587-4593. PubMed ID: 28716556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005-19: a cohort observational study.
    von Gottberg A; Kleynhans J; de Gouveia L; Tempia S; Meiring S; Quan V; du Plessis M; von Mollendorf C; Crowther-Gibson P; Avenant T; du Plessis N; Kularatne R; Chibabhai V; Madhi SA; Klugman KP; Whitney CG; Cohen C;
    Lancet Glob Health; 2024 Sep; 12(9):e1470-e1484. PubMed ID: 39151982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of invasive pneumococcal disease in indigenous and non-indigenous adults in northwestern Ontario, Canada, 2006-2015.
    Dalcin D; Sieswerda L; Dubois S; Ulanova M
    BMC Infect Dis; 2018 Dec; 18(1):621. PubMed ID: 30514226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs.
    Shigayeva A; Rudnick W; Green K; Chen DK; Demczuk W; Gold WL; Johnstone J; Kitai I; Krajden S; Lovinsky R; Muller M; Powis J; Rau N; Walmsley S; Tyrrell G; Bitnun A; McGeer A;
    Clin Infect Dis; 2016 Jan; 62(2):139-47. PubMed ID: 26354970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
    Link-Gelles R; Taylor T; Moore MR;
    Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
    Suga S; Chang B; Asada K; Akeda H; Nishi J; Okada K; Wakiguchi H; Maeda A; Oda M; Ishiwada N; Saitoh A; Oishi T; Hosoya M; Togashi T; Oishi K; Ihara T
    Vaccine; 2015 Nov; 33(45):6054-60. PubMed ID: 26235372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.